{"id":"e942564e-4942-5137-a725-67607bcb130d","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-areds-beta-lung","predicate":"increases_in_trial","statement":"Lung cancers occurred in 2.0% with beta-carotene versus 0.9% without, predominantly among former smokers.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"14d3a9cf-9d98-56e4-baad-deaa27348b9c","mechanism_event_label":"The comparator carotenoid had a separate safety signal.","subject":{"id":"1733f941-666e-56d6-b664-02ef303154b9","slug":"areds2-beta-carotene-assignment","display_name":"AREDS2 randomized beta-carotene assignment","entity_type_key":"chemical_species"},"object":{"id":"330d7a68-255b-5e32-8a7f-8bdc06a889f8","slug":"human-lung-cancer-incidence","display_name":"Human lung cancer incidence","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"14d3a9cf-9d98-56e4-baad-deaa27348b9c","stable_key":"cfa4bd86-d88d-555a-975c-68877bf00e0f:lutein-areds-beta-lung-event","event_type":"observed_intervention","label":"The comparator carotenoid had a separate safety signal.","description":"Lung cancers occurred in 2.0% with beta-carotene versus 0.9% without, predominantly among former smokers.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"73c24cd4-9ae8-5897-8359-fa4d9e8edecb","slug":"beta-carotene","display_name":"All-trans-beta-carotene","entity_type_key":"small_molecule"},"role":"tested_component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"1733f941-666e-56d6-b664-02ef303154b9","slug":"areds2-beta-carotene-assignment","display_name":"AREDS2 randomized beta-carotene assignment","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"330d7a68-255b-5e32-8a7f-8bdc06a889f8","slug":"human-lung-cancer-incidence","display_name":"Human lung cancer incidence","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/lutein-research/23644932.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"1bd379926e56d7243222c2ef69d6367b74aede2b02faabfb77fadcbadf95008f\", \"start_char\": 0, \"end_char\": 3037, \"text_sha256\": \"1bd379926e56d7243222c2ef69d6367b74aede2b02faabfb77fadcbadf95008f\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"AREDS2 phase 3 factorial randomized trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Lutein 10 mg + zeaxanthin 2 mg daily; background AREDS formula; median five years","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Combination and background treatment prevent attribution to lutein alone; primary contrast differs from replacement and main-effects analyses. Published correction 10.1001/jama.2013.6403 changes the Table 3 lung-neoplasm row label and Table 4 lung-neoplasm entries. These records use the indexed abstract and do not reproduce the uncorrected Table 4. Correction: https://jamanetwork.com/journals/jama/fullarticle/1710434 .","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Lutein research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"lutein","display_name":"Lutein","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"4203 adults aged 50–85 at elevated AMD progression risk","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The comparator carotenoid had a separate safety signal.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[lutein-p23644932] Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. (2013). https://pubmed.ncbi.nlm.nih.gov/23644932/ DOI: 10.1001/jama.2013.4997","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Eyes with large drusen and/or fellow-eye advanced AMD","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"027ba599-80de-53d8-b880-7885a8f2ed3c","evidence_kind":"source_excerpt","locator":"Lines 736-747","start_line":736,"end_line":747,"excerpt":"### lutein-areds-beta-lung\nLung cancers occurred in 2.0% with beta-carotene versus 0.9% without, predominantly among former smokers.\nCondition category: normal\nnutrient_topic: Lutein research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The comparator carotenoid had a separate safety signal.\norganism: 4203 adults aged 50–85 at elevated AMD progression risk\ntissue_or_cell_type: Eyes with large drusen and/or fellow-eye advanced AMD\nexperimental_model: AREDS2 phase 3 factorial randomized trial\nlimitations: Combination and background treatment prevent attribution to lutein alone; primary contrast differs from replacement and main-effects analyses. Published correction 10.1001/jama.2013.6403 changes the Table 3 lung-neoplasm row label and Table 4 lung-neoplasm entries. These records use the indexed abstract and do not reproduce the uncorrected Table 4. Correction: https://jamanetwork.com/journals/jama/fullarticle/1710434 .\nexposure: Lutein 10 mg + zeaxanthin 2 mg daily; background AREDS formula; median five years\nevidence_span: {\"source_cache\": \"artifacts/lutein-research/23644932.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"1bd379926e56d7243222c2ef69d6367b74aede2b02faabfb77fadcbadf95008f\", \"start_char\": 0, \"end_char\": 3037, \"text_sha256\": \"1bd379926e56d7243222c2ef69d6367b74aede2b02faabfb77fadcbadf95008f\"}\n[lutein-p23644932] Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. (2013). https://pubmed.ncbi.nlm.nih.gov/23644932/ DOI: 10.1001/jama.2013.4997","model_system":"AREDS2 phase 3 factorial randomized trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [lutein-p23644932] Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. (2013). https://pubmed.ncbi.nlm.nih.gov/23644932/ DOI: 10.1001/jama.2013.4997","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"beef4241-6ebd-5b36-864c-6ef3ed7e61b8","stable_key":"import-cfa4bd86-d88d-555a-975c-68877bf00e0f","title":"Lutein: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"1514ec459913a7044b4c4e1012ed367bcb918298181ebabd2a9e2ccecd789053","revision_id":"bae2c856-0785-546f-b08f-869318c27f9e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}